These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 38672070)

  • 1. Role of Breast Cancer Risk Estimation Models to Identify Women Eligible for Genetic Testing and Risk-Reducing Surgery.
    Irelli A; Patruno LV; Chiatamone Ranieri S; Di Giacomo D; Malatesta S; Alesse E; Tessitore A; Cannita K
    Biomedicines; 2024 Mar; 12(4):. PubMed ID: 38672070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.
    Foretová L; Navrátilová M; Svoboda M; Vašíčková P; Sťahlová EH; Házová J; Kleiblová P; Kleibl Z; Macháčková E; Palácová M; Petráková K
    Klin Onkol; 2019; 32(Supplementum2):6-13. PubMed ID: 31409076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer.
    Wei X; Sun L; Slade E; Fierheller CT; Oxley S; Kalra A; Sia J; Sideris M; McCluggage WG; Bromham N; Dworzynski K; Rosenthal AN; Brentnall A; Duffy S; Evans DG; Yang L; Legood R; Manchanda R
    JAMA Netw Open; 2024 Feb; 7(2):e2355324. PubMed ID: 38334999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline variants in DNA repair genes associated with hereditary breast and ovarian cancer syndrome: analysis of a 21 gene panel in the Brazilian population.
    da Costa E Silva Carvalho S; Cury NM; Brotto DB; de Araujo LF; Rosa RCA; Texeira LA; Plaça JR; Marques AA; Peronni KC; Ruy PC; Molfetta GA; Moriguti JC; Carraro DM; Palmero EI; Ashton-Prolla P; de Faria Ferraz VE; Silva WA
    BMC Med Genomics; 2020 Feb; 13(1):21. PubMed ID: 32039725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer.
    Öfverholm A; Törngren T; Rosén A; Arver B; Einbeigi Z; Haraldsson K; Ståhlbom AK; Kuchinskaya E; Lindblom A; Melin B; Paulsson-Karlsson Y; Stenmark-Askmalm M; Tham E; von Wachenfeldt A; Kvist A; Borg Å; Ehrencrona H
    BMC Cancer; 2023 Aug; 23(1):738. PubMed ID: 37563628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer.
    Hauke J; Horvath J; Groß E; Gehrig A; Honisch E; Hackmann K; Schmidt G; Arnold N; Faust U; Sutter C; Hentschel J; Wang-Gohrke S; Smogavec M; Weber BHF; Weber-Lassalle N; Weber-Lassalle K; Borde J; Ernst C; Altmüller J; Volk AE; Thiele H; Hübbel V; Nürnberg P; Keupp K; Versmold B; Pohl E; Kubisch C; Grill S; Paul V; Herold N; Lichey N; Rhiem K; Ditsch N; Ruckert C; Wappenschmidt B; Auber B; Rump A; Niederacher D; Haaf T; Ramser J; Dworniczak B; Engel C; Meindl A; Schmutzler RK; Hahnen E
    Cancer Med; 2018 Apr; 7(4):1349-1358. PubMed ID: 29522266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management.
    Yoshimura A; Imoto I; Iwata H
    Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline testing of
    Woodward ER; Lalloo F; Forde C; Pugh S; Burghel GJ; Schlecht H; Harkness EF; Howell A; Howell SJ; Gandhi A; Evans DG
    J Med Genet; 2024 Mar; 61(4):385-391. PubMed ID: 38123987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of non-BRCA genes in the indication of risk-reducing surgery in hereditary breast and ovarian cancer syndrome (HBOC).
    Fernández Madrigal L; Rodríguez Garcés MY; Jiménez Ruiz FJ
    Curr Probl Cancer; 2023 Dec; 47(6):101008. PubMed ID: 37704491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients.
    Gervas P; Molokov A; Ivanova A; Panferova Y; Kiselev A; Chernyshova A; Pisareva L; Choynzonov E; Cherdyntseva N
    Exp Oncol; 2021 Mar; 43(1):52-55. PubMed ID: 33785725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
    Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
    J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
    Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D
    Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families.
    Castéra L; Harter V; Muller E; Krieger S; Goardon N; Ricou A; Rousselin A; Paimparay G; Legros A; Bruet O; Quesnelle C; Domin F; San C; Brault B; Fouillet R; Abadie C; Béra O; Berthet P; ; Frébourg T; Vaur D
    Genet Med; 2018 Dec; 20(12):1677-1686. PubMed ID: 29988077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended gene panel testing in lobular breast cancer.
    van Veen EM; Evans DG; Harkness EF; Byers HJ; Ellingford JM; Woodward ER; Bowers NL; Wallace AJ; Howell SJ; Howell A; Lalloo F; Newman WG; Smith MJ
    Fam Cancer; 2022 Apr; 21(2):129-136. PubMed ID: 33763779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women.
    Kurian AW; Hughes E; Handorf EA; Gutin A; Allen B; Hartman AR; Hall MJ
    JCO Precis Oncol; 2017 Nov; 1():1-12. PubMed ID: 35172496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Demographics and Clinical Decision Making in Patients with Germline Moderate Penetrance Non-BRCA Mutations in Breast Cancer Related Genes.
    Ntowe KW; Thomas SM; Dalton JC; Olunuga E; Wang T; Chiba A; Plichta JK
    Ann Surg Oncol; 2024 Jul; ():. PubMed ID: 38976158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective.
    Molina-Zayas M; Garrido-Navas C; García-Puche JL; Barwell J; Pedrinaci S; Atienza MM; García-Linares S; de Haro-Muñoz T; Lorente JA; Serrano MJ; Poyatos-Andújar A
    Mol Genet Genomics; 2022 May; 297(3):859-871. PubMed ID: 35451682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
    Graffeo R; Rana HQ; Conforti F; Bonanni B; Cardoso MJ; Paluch-Shimon S; Pagani O; Goldhirsch A; Partridge AH; Lambertini M; Garber JE
    Breast; 2022 Oct; 65():32-40. PubMed ID: 35772246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High frequency of pathogenic non-founder germline mutations in
    Maksimenko J; Irmejs A; Trofimovičs G; Bērziņa D; Skuja E; Purkalne G; Miklaševičs E; Gardovskis J
    Hered Cancer Clin Pract; 2018; 16():12. PubMed ID: 29928469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.